Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer
M Nakagawa, Y Bando, T Nagao, M Morimoto… - Anticancer …, 2011 - ar.iiarjournals.org
Background: Elucidation of the biological features of triple negative breast cancer (TNBC) is
important for deciding treatment strategies. The expression of a number of biomarkers in …
important for deciding treatment strategies. The expression of a number of biomarkers in …
Preoperative diagnosis of sentinel lymph node (SLN) metastasis using 3D CT lymphography (CTLG)
M Nakagawa, M Morimoto, H Takechi, Y Tadokoro… - Breast Cancer, 2016 - Springer
Background Sentinel lymph node biopsy (SLNB) became a standard procedure for patients
with early breast cancer, however, an indication of SLN navigation to metastatic disease may …
with early breast cancer, however, an indication of SLN navigation to metastatic disease may …
Triple assessment of sentinel lymph node metastasis in early breast cancer using preoperative CTLG, intraoperative fluorescence navigation and OSNA
M Mokhtar, Y Tadokoro, M Nakagawa, M Morimoto… - Breast Cancer, 2016 - Springer
Background Sentinel lymph node biopsy (SLNB) became a standard surgical procedure for
patients with early breast cancer; however, the optimal method of sentinel lymph node (SLN) …
patients with early breast cancer; however, the optimal method of sentinel lymph node (SLN) …
[HTML][HTML] The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia
…, M Morimoto, J Honda, T Nagao, M Nakagawa… - BMC cancer, 2011 - Springer
Background The clinical predictors of aromatase inhibitor-related arthralgia (AIA), a drug-related
adverse reaction of aromatase inhibitors (AIs), remain unclear. Methods AIA was …
adverse reaction of aromatase inhibitors (AIs), remain unclear. Methods AIA was …
Long-term outcomes of S-1 combined with low-dose docetaxel as neoadjuvant chemotherapy (N-1 study, phase II trial) in patients with operable breast cancer
S Sasa, H Inoue, M Nakagawa, H Toba, M Goto… - Clinical Breast …, 2024 - Elsevier
Background We previously reported that S-1 and low-dose docetaxel (DOC) (N-1 study,
phase II trial) could be a well-tolerated and effective neoadjuvant chemotherapies (NACs) for …
phase II trial) could be a well-tolerated and effective neoadjuvant chemotherapies (NACs) for …
Among triple-negative breast cancers, HER2 (0) breast cancer shows a strong tendency to be basal-like compared with HER2 (1+) breast cancer: preliminary results
M Nakagawa, Y Bando, T Nagao, C Takai, T Ohnishi… - Breast Cancer, 2012 - Springer
Background Diagnosis of triple-negative breast cancer (ER-negative, PgR-negative, HER2-negative;
TNBC) is performed by means of immunohistological staining. HER2-negative …
TNBC) is performed by means of immunohistological staining. HER2-negative …
Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable
M Morimoto, Y Bando, M Nakagawa, H Takechi… - Breast cancer, 2016 - Springer
Background Re-evaluation of the subtype of recurrent breast cancer is necessary for deciding
the treatment approach, but it is often not performed due to the difficulty of obtaining tissue …
the treatment approach, but it is often not performed due to the difficulty of obtaining tissue …
Phase II study of S-1 combined with low-dose docetaxel as neoadjuvant chemotherapy for operable breast cancer patients (N-1 study)
M Nakagawa, M Ikeuchi, M Morimoto, H Takechi… - Clinical Breast …, 2019 - Elsevier
Background To improve the pathological complete response (pCR) rate, we devised new
neoadjuvant chemotherapy. Efficacy and safety of the oral fluoropyrimidine derivative S-1 (…
neoadjuvant chemotherapy. Efficacy and safety of the oral fluoropyrimidine derivative S-1 (…
Phase 1 dose-escalation study of triweekly nab-paclitaxel combined with S-1 for HER2-negative metastatic breast cancer
M Morimoto, H Toba, M Aoyama, M Nakagawa… - Clinical Breast …, 2020 - Elsevier
Purpose To evaluate the efficacy, toxicity, maximum tolerated dose, and recommended dose
of triweekly nab-paclitaxel (nab-PTX) and S-1 combination chemotherapy for patients with …
of triweekly nab-paclitaxel (nab-PTX) and S-1 combination chemotherapy for patients with …
[HTML][HTML] Joint symptoms, aromatase inhibitor-related adverse reactions, are indirectly associated with decreased serum estradiol
J Honda, M Kanematsu, M Nakagawa… - International Journal of …, 2011 - hindawi.com
Background. Joint symptoms (JSs) are problematic adverse drug reactions (ADRs) of
aromatase inhibitors (AIs). Involvement of decreased serum estradiol (SE) has been suggested. …
aromatase inhibitors (AIs). Involvement of decreased serum estradiol (SE) has been suggested. …